David A. Siegel Kymera Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 367,000 shares of KYMR stock, worth $17.4 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
367,000
Previous 209,100
75.51%
Holding current value
$17.4 Million
Previous $8.41 Million
30.33%
% of portfolio
0.03%
Previous 0.02%
Shares
11 transactions
Others Institutions Holding KYMR
# of Institutions
160Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$302 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$284 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$253 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$244 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$228 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.59B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...